 Mary Demoruelle
Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 64 | 2025 | 1098 | 11.100 |
Why?
| | Anti-Citrullinated Protein Antibodies | 19 | 2025 | 109 | 4.800 |
Why?
| | Autoantibodies | 35 | 2025 | 1468 | 4.550 |
Why?
| | Lung Diseases, Interstitial | 14 | 2025 | 611 | 3.520 |
Why?
| | Connective Tissue Diseases | 5 | 2024 | 82 | 2.970 |
Why?
| | Sputum | 5 | 2025 | 302 | 2.530 |
Why?
| | Immunoglobulin A | 10 | 2023 | 201 | 2.380 |
Why?
| | Extracellular Traps | 4 | 2023 | 49 | 2.230 |
Why?
| | Peptides, Cyclic | 13 | 2023 | 256 | 2.010 |
Why?
| | Idiopathic Pulmonary Fibrosis | 6 | 2023 | 634 | 1.980 |
Why?
| | Immunity, Mucosal | 4 | 2020 | 94 | 1.770 |
Why?
| | Autoimmunity | 11 | 2025 | 863 | 1.680 |
Why?
| | Rheumatoid Factor | 12 | 2025 | 167 | 0.980 |
Why?
| | Pulmonary Fibrosis | 2 | 2025 | 385 | 0.900 |
Why?
| | Infertility, Female | 1 | 2024 | 102 | 0.870 |
Why?
| | Fertility | 1 | 2024 | 156 | 0.840 |
Why?
| | Antiphospholipid Syndrome | 1 | 2023 | 37 | 0.820 |
Why?
| | Citrullination | 3 | 2020 | 12 | 0.800 |
Why?
| | Bronchial Diseases | 2 | 2013 | 37 | 0.790 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 462 | 0.790 |
Why?
| | Citrulline | 3 | 2020 | 43 | 0.710 |
Why?
| | Humans | 72 | 2025 | 129687 | 0.690 |
Why?
| | Microbiota | 3 | 2021 | 734 | 0.680 |
Why?
| | Pregnancy Complications | 1 | 2024 | 493 | 0.650 |
Why?
| | Inflammation | 5 | 2022 | 2748 | 0.640 |
Why?
| | Lupus Erythematosus, Systemic | 3 | 2022 | 247 | 0.620 |
Why?
| | Autoantigens | 4 | 2022 | 420 | 0.580 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2023 | 836 | 0.570 |
Why?
| | Lung | 8 | 2023 | 3937 | 0.550 |
Why?
| | Pedigree | 2 | 2020 | 483 | 0.540 |
Why?
| | Antirheumatic Agents | 2 | 2024 | 280 | 0.520 |
Why?
| | Lung Diseases | 2 | 2013 | 741 | 0.500 |
Why?
| | Middle Aged | 33 | 2025 | 31165 | 0.480 |
Why?
| | Aged | 22 | 2025 | 22101 | 0.450 |
Why?
| | Pneumonia | 1 | 2020 | 619 | 0.440 |
Why?
| | Female | 40 | 2025 | 68751 | 0.420 |
Why?
| | Male | 37 | 2025 | 63691 | 0.390 |
Why?
| | Asymptomatic Diseases | 1 | 2012 | 84 | 0.380 |
Why?
| | Arthritis | 1 | 2012 | 90 | 0.370 |
Why?
| | Pneumonia, Bacterial | 1 | 2013 | 115 | 0.370 |
Why?
| | Respiration Disorders | 2 | 2022 | 72 | 0.370 |
Why?
| | Mucin-5B | 2 | 2025 | 215 | 0.360 |
Why?
| | Case-Control Studies | 10 | 2025 | 3381 | 0.360 |
Why?
| | Protein-Arginine Deiminases | 3 | 2021 | 16 | 0.360 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2017 | 138 | 0.350 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 428 | 0.350 |
Why?
| | Risk Factors | 15 | 2022 | 9787 | 0.350 |
Why?
| | Respiratory Insufficiency | 1 | 2013 | 313 | 0.310 |
Why?
| | Adult | 25 | 2025 | 35607 | 0.310 |
Why?
| | Respiratory Function Tests | 3 | 2025 | 581 | 0.310 |
Why?
| | Prospective Studies | 13 | 2025 | 7145 | 0.300 |
Why?
| | Tomography, X-Ray Computed | 4 | 2025 | 2510 | 0.280 |
Why?
| | Histones | 3 | 2021 | 588 | 0.270 |
Why?
| | Disease Progression | 8 | 2024 | 2628 | 0.270 |
Why?
| | Neutrophils | 2 | 2023 | 1209 | 0.260 |
Why?
| | Epitopes | 5 | 2023 | 474 | 0.260 |
Why?
| | Biomarkers | 6 | 2025 | 3969 | 0.250 |
Why?
| | Chlamydia trachomatis | 1 | 2025 | 46 | 0.230 |
Why?
| | Intestines | 2 | 2021 | 349 | 0.230 |
Why?
| | Chlamydia Infections | 1 | 2025 | 72 | 0.220 |
Why?
| | Adenylate Kinase | 1 | 2023 | 26 | 0.210 |
Why?
| | Genetic Predisposition to Disease | 3 | 2022 | 2271 | 0.210 |
Why?
| | Scleroderma, Systemic | 1 | 2024 | 114 | 0.210 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2024 | 135 | 0.210 |
Why?
| | Antibody Formation | 3 | 2022 | 291 | 0.210 |
Why?
| | HLA-DR Antigens | 1 | 2024 | 223 | 0.200 |
Why?
| | Incidence | 5 | 2021 | 2644 | 0.200 |
Why?
| | Immunosuppressive Agents | 2 | 2024 | 858 | 0.190 |
Why?
| | Dysbiosis | 2 | 2020 | 170 | 0.180 |
Why?
| | Hydrolases | 1 | 2021 | 56 | 0.180 |
Why?
| | Neutrophil Activation | 1 | 2021 | 80 | 0.170 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 95 | 0.170 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2021 | 97 | 0.170 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2020 | 8 | 0.170 |
Why?
| | Chemokine CXCL16 | 1 | 2020 | 4 | 0.170 |
Why?
| | Vimentin | 1 | 2020 | 51 | 0.170 |
Why?
| | Early Diagnosis | 3 | 2022 | 233 | 0.170 |
Why?
| | Milk Proteins | 1 | 2020 | 34 | 0.170 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 189 | 0.170 |
Why?
| | Muramidase | 1 | 2020 | 77 | 0.160 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 179 | 0.160 |
Why?
| | Bacteriophages | 1 | 2021 | 86 | 0.160 |
Why?
| | Malondialdehyde | 1 | 2019 | 29 | 0.160 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2020 | 86 | 0.160 |
Why?
| | Acetaldehyde | 1 | 2019 | 17 | 0.160 |
Why?
| | Antibodies, Bacterial | 1 | 2020 | 139 | 0.160 |
Why?
| | Mammary Glands, Animal | 1 | 2020 | 128 | 0.160 |
Why?
| | Nuclear Family | 1 | 2019 | 51 | 0.160 |
Why?
| | Family Characteristics | 1 | 2020 | 180 | 0.150 |
Why?
| | Immunoglobulin G | 5 | 2023 | 851 | 0.150 |
Why?
| | Lactation | 1 | 2020 | 175 | 0.150 |
Why?
| | Leukocytes, Mononuclear | 2 | 2024 | 546 | 0.150 |
Why?
| | Occupational Exposure | 1 | 2022 | 299 | 0.150 |
Why?
| | B-Lymphocytes | 1 | 2024 | 816 | 0.150 |
Why?
| | Arthritis, Experimental | 1 | 2020 | 135 | 0.150 |
Why?
| | Monocytes | 1 | 2020 | 553 | 0.140 |
Why?
| | Mucous Membrane | 1 | 2018 | 125 | 0.140 |
Why?
| | Prevalence | 2 | 2022 | 2563 | 0.130 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2016 | 46 | 0.130 |
Why?
| | Plasma Cells | 1 | 2016 | 66 | 0.130 |
Why?
| | Complement System Proteins | 1 | 2019 | 319 | 0.130 |
Why?
| | Peptides | 1 | 2021 | 926 | 0.120 |
Why?
| | Mitochondria | 1 | 2021 | 875 | 0.110 |
Why?
| | Molecular Mimicry | 1 | 2014 | 38 | 0.110 |
Why?
| | Immunoglobulin M | 3 | 2022 | 276 | 0.110 |
Why?
| | Animals | 5 | 2023 | 35404 | 0.110 |
Why?
| | Cross-Sectional Studies | 5 | 2023 | 5083 | 0.110 |
Why?
| | Mice | 4 | 2023 | 16982 | 0.110 |
Why?
| | Mouth Mucosa | 1 | 2014 | 89 | 0.110 |
Why?
| | Young Adult | 3 | 2021 | 12457 | 0.100 |
Why?
| | Pneumocystis carinii | 1 | 2013 | 11 | 0.100 |
Why?
| | Mass Screening | 1 | 2020 | 1192 | 0.100 |
Why?
| | Stress, Psychological | 1 | 2020 | 1070 | 0.100 |
Why?
| | Population Surveillance | 1 | 2015 | 439 | 0.100 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 1844 | 0.100 |
Why?
| | Prognosis | 2 | 2021 | 3772 | 0.100 |
Why?
| | Arthrography | 1 | 2011 | 17 | 0.100 |
Why?
| | Fatal Outcome | 1 | 2013 | 299 | 0.100 |
Why?
| | Pregnancy | 1 | 2024 | 6412 | 0.100 |
Why?
| | Remission Induction | 1 | 2012 | 274 | 0.090 |
Why?
| | Age Factors | 1 | 2019 | 3153 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2022 | 10221 | 0.090 |
Why?
| | Proportional Hazards Models | 3 | 2021 | 1199 | 0.090 |
Why?
| | Time-to-Treatment | 1 | 2012 | 179 | 0.090 |
Why?
| | Joints | 1 | 2011 | 101 | 0.090 |
Why?
| | Blood Pressure | 1 | 2017 | 1736 | 0.090 |
Why?
| | Time Factors | 3 | 2020 | 6545 | 0.090 |
Why?
| | Air Pollution | 1 | 2013 | 218 | 0.080 |
Why?
| | Disease Susceptibility | 2 | 2021 | 334 | 0.080 |
Why?
| | Vital Capacity | 2 | 2022 | 290 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1433 | 0.070 |
Why?
| | Organ Specificity | 2 | 2019 | 295 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1204 | 0.060 |
Why?
| | Cohort Studies | 3 | 2022 | 5434 | 0.060 |
Why?
| | Family | 2 | 2021 | 646 | 0.060 |
Why?
| | Switzerland | 1 | 2025 | 36 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2739 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2021 | 1500 | 0.060 |
Why?
| | Receptors, CXCR5 | 1 | 2024 | 21 | 0.060 |
Why?
| | Smoking | 2 | 2024 | 1502 | 0.060 |
Why?
| | Telomere Shortening | 1 | 2024 | 20 | 0.050 |
Why?
| | Azathioprine | 1 | 2022 | 50 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 34 | 0.050 |
Why?
| | Rituximab | 1 | 2022 | 164 | 0.050 |
Why?
| | Telomere | 1 | 2024 | 232 | 0.050 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2021 | 42 | 0.050 |
Why?
| | Arthralgia | 1 | 2021 | 49 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 157 | 0.040 |
Why?
| | Vitamins | 1 | 2022 | 173 | 0.040 |
Why?
| | Genetic Markers | 1 | 2022 | 334 | 0.040 |
Why?
| | Cytokines | 2 | 2020 | 2022 | 0.040 |
Why?
| | Docosahexaenoic Acids | 1 | 2021 | 82 | 0.040 |
Why?
| | Synovial Fluid | 1 | 2020 | 66 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2024 | 1160 | 0.040 |
Why?
| | Acute-Phase Proteins | 1 | 2020 | 67 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2021 | 264 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2020 | 377 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2020 | 131 | 0.040 |
Why?
| | Prolactin | 1 | 2020 | 97 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2020 | 185 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2020 | 310 | 0.040 |
Why?
| | Colorado | 2 | 2020 | 4405 | 0.040 |
Why?
| | Endotoxins | 1 | 2020 | 220 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2021 | 369 | 0.040 |
Why?
| | Methotrexate | 1 | 2020 | 249 | 0.040 |
Why?
| | Vitamin D | 1 | 2022 | 380 | 0.040 |
Why?
| | Arginine | 1 | 2020 | 262 | 0.040 |
Why?
| | Tobacco Products | 1 | 2019 | 110 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 592 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2022 | 602 | 0.040 |
Why?
| | Gene Frequency | 1 | 2019 | 500 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2020 | 505 | 0.040 |
Why?
| | Genetic Testing | 1 | 2020 | 422 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4892 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 477 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 457 | 0.030 |
Why?
| | Phylogeny | 1 | 2021 | 845 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2021 | 724 | 0.030 |
Why?
| | Environment | 1 | 2019 | 345 | 0.030 |
Why?
| | Genes, Immunoglobulin Light Chain | 1 | 2016 | 5 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2016 | 9 | 0.030 |
Why?
| | Phosphofructokinase-2 | 1 | 2016 | 15 | 0.030 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 65 | 0.030 |
Why?
| | Complement Activation | 1 | 2019 | 385 | 0.030 |
Why?
| | Alleles | 1 | 2019 | 843 | 0.030 |
Why?
| | Protective Factors | 1 | 2016 | 91 | 0.030 |
Why?
| | Th17 Cells | 1 | 2016 | 85 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2020 | 741 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1368 | 0.030 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2015 | 74 | 0.030 |
Why?
| | Proteome | 1 | 2020 | 440 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2016 | 437 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2022 | 14525 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1021 | 0.030 |
Why?
| | Gene Expression | 1 | 2020 | 1465 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 875 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1270 | 0.030 |
Why?
| | Immunoglobulins | 1 | 2015 | 162 | 0.030 |
Why?
| | Forced Expiratory Volume | 1 | 2015 | 508 | 0.030 |
Why?
| | Risk | 1 | 2016 | 855 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 778 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 1058 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 851 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2724 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2016 | 486 | 0.030 |
Why?
| | Geographic Information Systems | 1 | 2013 | 42 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2020 | 2702 | 0.020 |
Why?
| | Cell Membrane | 1 | 2016 | 734 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2020 | 4102 | 0.020 |
Why?
| | United States | 2 | 2022 | 13906 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2016 | 532 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2062 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3260 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 1872 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 3705 | 0.020 |
Why?
| | Particulate Matter | 1 | 2013 | 247 | 0.020 |
Why?
| | Body Mass Index | 1 | 2019 | 2274 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2013 | 309 | 0.020 |
Why?
| | Erythrocytes | 1 | 2016 | 673 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2013 | 401 | 0.020 |
Why?
| | Exercise | 1 | 2021 | 1933 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2545 | 0.020 |
Why?
| | Adolescent | 1 | 2021 | 20415 | 0.010 |
Why?
|
|
Demoruelle's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|